iCAD, Inc. Launches Post-Market Study of Intra-Operative Radiation Therapy to Treat Early Stage Breast Cancer
Published: Mar 15, 2012
NASHUA, N.H. & MIAMI--(BUSINESS WIRE)--iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announced today the launch of a post-market study to assess the safety and efficacy of the company’s FDA-cleared Xoft Axxent® eBx™ System when used for single-fraction, intra-operative radiation therapy (IORT) at the time of lumpectomy for early stage breast cancer. A historical comparison will be made to the current standard of care, external beam radiation therapy (EBRT). The announcement was made during the 29th Annual Miami Breast Cancer Conference where iCAD is showcasing the Xoft System.